A Senescence Program Controlled by p53 and p16INK4a Contributes to the Outcome of Cancer Therapy
Top Cited Papers
- 1 May 2002
- Vol. 109 (3) , 335-346
- https://doi.org/10.1016/s0092-8674(02)00734-1
Abstract
No abstract availableKeywords
This publication has 35 references indexed in Scilit:
- Cellular senescence as a tumor-suppressor mechanismTrends in Cell Biology, 2001
- Dual Inactivation of RB and p53 Pathways in RAS-Induced MelanomasMolecular and Cellular Biology, 2001
- Genetic determinants of response to chemotherapy in transgenic mouse mammary and salivary tumorsOncogene, 2000
- p16INK4A and p19ARF act in overlapping pathways in cellular immortalizationNature Cell Biology, 2000
- Disruption of p53 in human cancer cells alters the responses to therapeutic agentsJournal of Clinical Investigation, 1999
- Requirement for p53 and p21 to Sustain G 2 Arrest After DNA DamageScience, 1998
- E1A signaling to p53 involves the p19ARFtumor suppressorGenes & Development, 1998
- Involvement of the cyclin-dependent kinase inhibitor p16 (INK4a) in replicative senescence of normal human fibroblastsProceedings of the National Academy of Sciences, 1996
- DNA damage triggers a prolonged p53-dependent G1 arrest and long-term induction of Cip1 in normal human fibroblasts.Genes & Development, 1994
- The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic miceNature, 1985